Primary Fibromyalgia
3
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Tonix PharmaceuticalsBERKELEY HEIGHTS, NJ
3 programs1
2
TNX-102 SLPhase 31 trial
TNX-102 SL Tablet 2.8 mgPhase 31 trial
TNX-102 SL 2.8mgPhase 2/31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Tonix PharmaceuticalsTNX-102 SL Tablet 2.8 mg
Tonix PharmaceuticalsTNX-102 SL
Tonix PharmaceuticalsTNX-102 SL 2.8mg
Clinical Trials (3)
Total enrollment: 738 patients across 3 trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Start: Aug 2015Est. completion: Sep 2016375 patients
Phase 3Completed
12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients
Start: Dec 2013Est. completion: Aug 2015158 patients
Phase 3Completed
BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)
Start: Sep 2013Est. completion: Sep 2014205 patients
Phase 2/3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space